Company intelligence / Profile preview

Mist

Montreal, Quebec, Canada

Ownership: Private
Employees: ~33
Development stage: Other

Overview

Milestone Pharmaceuticals received FDA approval of CARDAMYST (etripamil) in December 2025 for paroxysmal supraventricular tachycardia, marking its transition to commercial-stage operations. Etripamil demonstrated efficacy in Phase 3 trials (RAPID and NODE-301), significantly increasing conversion to sinus rhythm compared to placebo. The product is also in Phase 2 development for atrial fibrillation with rapid ventricular rate.[1][3][4]

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Corxel Pharmaceuticals

Beyond the preview

Go deeper on Mist.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mist.

Explore the full profile